Reckitt Benckiser Group plc (RKT) has announced the admission to trading of EUR 650 million floating rate notes on the London Stock Exchange's main market, effective 9 November 2026. The notes were issued by Reckitt Benckiser Treasury Services plc under the group's existing GBP 10 billion Euro Medium Term Note Programme. The two-year instruments carry a floating rate of 3-month EURIBOR plus 0.55 per cent and mature on 9 November 2028. Investors in the consumer health and hygiene giant may note this as a significant capital markets activity under a well-established funding framework.

Key Points

  • Reckitt Benckiser Group plc (RKT) — global consumer health and hygiene company founded in 1840
  • EUR 650 million floating rate notes admitted to trading on the London Stock Exchange's main market on 9 November 2026
  • Notes carry a rate of 3-month EURIBOR + 0.55%, mature 9 November 2028, ISIN: XS3562431612, issued under the GBP 10 billion EMTN Programme
  • Investors should watch for further EMTN issuances and updates to Reckitt's broader funding strategy

Reckitt Benckiser Treasury Services Issues EUR 650 Million Two-Year Floating Rate Notes

The notes were issued by Reckitt Benckiser Treasury Services plc, the group's dedicated financing entity, under the GBP 10 billion Euro Medium Term Note Programme. The floating rate instrument is priced at 3-month EURIBOR plus 0.55 per cent, reflecting current short-term euro interest rate benchmarks. Maturing on 9 November 2028, the notes carry ISIN XS3562431612 and were formally admitted to trading on the London Stock Exchange's main market on 9 November 2026. The base prospectus underpinning this issuance is dated 30 October 2026, with final terms published on 5 November 2026.

GBP 10 Billion EMTN Programme Underpins Reckitt's Debt Capital Markets Activity

The Euro Medium Term Note Programme, with a total capacity of GBP 10 billion, provides Reckitt with a flexible and established framework for accessing European debt capital markets. This structure allows the group to issue notes across varying maturities and currencies, supporting its broader treasury and liquidity management objectives. The base prospectus and final terms have been made available through the London Stock Exchange's regulatory news service, the company's investor relations website, and the Financial Conduct Authority's National Storage Mechanism, ensuring full regulatory transparency for market participants.

Reckitt's Global Consumer Health Portfolio Provides the Commercial Backdrop to This Issuance

Reckitt operates across more than 80 countries and employs approximately 36,000 people worldwide, selling around 30 million products daily. Its portfolio spans Germ Protection, Household Care, Intimate Wellness and Self Care, with brands including Dettol, Durex, Nurofen, Gaviscon, Mucinex, Strepsils, Finish, Harpic, Vanish and Veet. Founded in 1840 in the United Kingdom, the group positions itself as a science-led consumer health and hygiene business. This commercial scale provides the revenue base against which Reckitt's treasury operations, including debt issuances such as this one, are conducted.

Regulatory Restrictions Limit Availability of the Notes to Non-US Investors

The announcement confirms that the notes have not been registered under the US Securities Act of 1933 and are subject to US tax law requirements. Subject to certain exceptions, the securities may not be offered, sold, or delivered in the United States or to US persons as defined under the US Internal Revenue Code. The base prospectus is similarly restricted from access within the United States. These are standard regulatory conditions for euro-denominated notes issued under European medium-term note programmes and reflect the jurisdiction-specific nature of this debt issuance.